SecSonar.com

Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Sangamo Therapeutics, Inc. (SGMO) is a Biotechnology company based in US with a market capitalization of $103.1M. Revenue declined 31.6% year-over-year and free cash flow was negative at -$97.3M. This page tracks SGMO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 183 employees · IPO Apr 6, 2000

Valuation

Valuation & price

$0.14 · as of May 17, 2026 · -81.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$0.70$0.39$0.07Jul 25Dec 25Jul 26Jul 7, 25$0.51Jul 9, 25$0.53Jul 11, 25$0.49Jul 15, 25$0.48Jul 17, 25$0.48Jul 21, 25$0.49Jul 23, 25$0.55Jul 25, 25$0.59Jul 29, 25$0.57Jul 31, 25$0.54Aug 4, 25$0.54Aug 6, 25$0.53Aug 8, 25$0.46Aug 12, 25$0.52Aug 15, 25$0.58Aug 19, 25$0.56Aug 21, 25$0.57Aug 25, 25$0.55Aug 27, 25$0.54Aug 29, 25$0.52Sep 3, 25$0.53Sep 5, 25$0.55Sep 9, 25$0.52Sep 11, 25$0.53Sep 15, 25$0.50Sep 17, 25$0.51Sep 19, 25$0.55Sep 24, 25$0.56Sep 26, 25$0.66Sep 30, 25$0.67Oct 2, 25$0.70Oct 6, 25$0.70Oct 8, 25$0.69Oct 10, 25$0.67Oct 14, 25$0.69Oct 16, 25$0.64Oct 20, 25$0.68Oct 22, 25$0.66Oct 24, 25$0.63Oct 28, 25$0.59Oct 31, 25$0.60Nov 4, 25$0.56Nov 6, 25$0.46Nov 10, 25$0.51Nov 12, 25$0.47Nov 14, 25$0.44Nov 18, 25$0.42Nov 20, 25$0.39Nov 24, 25$0.42Nov 26, 25$0.46Dec 1, 25$0.43Dec 3, 25$0.50Dec 5, 25$0.50Dec 9, 25$0.50Dec 12, 25$0.45Dec 16, 25$0.44Dec 18, 25$0.43Dec 22, 25$0.46Dec 24, 25$0.45Dec 29, 25$0.41Dec 31, 25$0.42Jan 5, 26$0.44Jan 7, 26$0.46Jan 9, 26$0.44Jan 13, 26$0.45Jan 15, 26$0.43Jan 20, 26$0.37Jan 23, 26$0.38Jan 27, 26$0.38Jan 29, 26$0.51Feb 2, 26$0.57Feb 4, 26$0.36Feb 6, 26$0.40Feb 10, 26$0.39Feb 12, 26$0.38Feb 17, 26$0.37Feb 19, 26$0.38Feb 23, 26$0.39Feb 25, 26$0.47Feb 27, 26$0.43Mar 4, 26$0.40Mar 6, 26$0.38Mar 10, 26$0.41Mar 12, 26$0.40Mar 16, 26$0.36Mar 18, 26$0.36Mar 20, 26$0.33Mar 24, 26$0.35Mar 26, 26$0.34Mar 30, 26$0.31Apr 1, 26$0.26Apr 6, 26$0.28Apr 8, 26$0.25Apr 10, 26$0.25Apr 15, 26$0.28Apr 17, 26$0.26Apr 21, 26$0.26Apr 23, 26$0.26Apr 27, 26$0.21Apr 29, 26$0.13May 1, 26$0.14May 5, 26$0.11May 7, 26$0.10May 11, 26$0.12May 13, 26$0.14May 15, 26$0.14May 19, 26$0.15May 22, 26$0.17May 27, 26$0.20May 29, 26$0.22Jun 2, 26$0.21Jun 4, 26$0.21Jun 8, 26$0.17Jun 10, 26$0.15Jun 12, 26$0.15Jun 16, 26$0.17Jun 18, 26$0.17Jun 23, 26$0.07Jun 25, 26$0.07Jul 1, 26$0.07
$0.0752-week range$0.74
Loading valuation history…

Fundamentals

Key fundamentals

$103.1M

Market cap

-31.6%

Revenue growth (YoY)

80.8%

Gross margin

-$97.3M

Free cash flow (USD)

$5.8M

Net debt

38.9%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$19.4MFY 2017$36.6MFY 2018$84.5MFY 2019$102.4MFY 2020$118.2MFY 2021$110.7MFY 2022$111.3MFY 2023$176.2MFY 2024$57.8MFY 2025$39.6M
$19.4M$39.6M

Free cash flow by year

2016 → 2025

FY 2016$-66.6MFY 2017$7.4MFY 2018$-5.9MFY 2019$-165.1MFY 2020$155.2MFY 2021$-256.5MFY 2022$-243.8MFY 2023$-246.0MFY 2024$-67.4MFY 2025$-97.3M
-$66.6M-$97.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202289.1%FY 2023100.0%FY 2024100.0%FY 202580.8%
100.0%80.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $-0.07)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventBankruptcy FilingJul 1, 2026Filing
  • 8-K eventAsset Purchase AgreementJun 23, 2026Filing
  • 8-K eventBankruptcy FilingJun 23, 2026Filing
  • 8-K eventBusiness Highlights and Financial ResultsMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • Annual report10-K FiledApr 30, 2026Filing
  • 8-K eventDelisting NoticeApr 29, 2026Filing
  • Insider sellInsider Sell $89KDubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICER · $89.2KApr 23, 2026Filing
  • Insider sellInsider Sell $18KDavis Gregory D · Head of Research & Technology · $17.7KApr 23, 2026Filing

Questions

Frequently asked questions

What is Sangamo Therapeutics, Inc.'s market cap?

Sangamo Therapeutics, Inc. (SGMO) has a market capitalization of $103.1M.

What is SGMO's P/E ratio?

A meaningful P/E ratio is not available for SGMO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

When did Sangamo Therapeutics, Inc. last report earnings?

SGMO last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying SGMO stock?

SEC Form 4 filings show no open-market insider buys at Sangamo Therapeutics, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

EQ

Equillium, Inc.

$103.2M

SEER

Seer, Inc.

$103.9M

ATRA

Atara Biotherapeutics, Inc.

$94.9M

CAMP

CAMP4 Therapeutics Corporation

$93.6M

FBIO

Fortress Biotech, Inc.

$93.3M

PYXS

Pyxis Oncology, Inc.

$113.7M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.